Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2012
08/16/2012WO2012064981A3 Methods to test allergic conditions
08/16/2012WO2012061907A3 Osteoclast activity
08/16/2012WO2012061413A3 Isoflavonoid compositions and methods for the treatment of cancer
08/16/2012WO2012061342A3 Substituted benzo-imidazo-pyrido-diazepine compounds
08/16/2012WO2012054920A3 Antigen-specific, tolerance-inducing microparticles and uses thereof
08/16/2012WO2012054447A3 Use of storage stable viscous phospholipid depot to treat wounds
08/16/2012WO2012051126A3 Anti-inflammatory macrolides
08/16/2012WO2012050918A8 Tricyclic fused ring inhibitors of hepatitis c
08/16/2012WO2012039596A3 Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
08/16/2012WO2012036919A3 Combination of braf and vegf inhibitors
08/16/2012WO2012036573A3 Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction
08/16/2012WO2012031603A3 Airway administration of angiogenesis inhibitors
08/16/2012WO2012030984A3 Skin compositions and methods of use thereof
08/16/2012WO2012028965A3 Combination of semax and choline alfoscerate with antihypoxic neuroprotective, and antiαμνesic action and with ability to improve physical efficiency
08/16/2012WO2012028276A3 Device for metering an acid-containing composition
08/16/2012WO2012016703A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
08/16/2012WO2012016699A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
08/16/2012WO2012016698A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
08/16/2012WO2012016697A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
08/16/2012WO2012016695A3 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
08/16/2012WO2012014052A4 Novel coated extended release pharmaceutical compositions containing paliperidone
08/16/2012WO2011154724A9 Injectable flowable composition comprising buprenorphine
08/16/2012WO2011105099A8 Compound containing a novel 4-alkoxypyrimidine formation and medicine containing same
08/16/2012WO2011092469A8 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
08/16/2012WO2008144483A3 Agents for treating disorders involving modulation of ryanodine receptors
08/16/2012WO2004053071A9 Method for discovering neurogenic agents
08/16/2012US20120210465 Production of Polyunsaturated Fatty Acids, Novel Biosynthesis Genes, And Novel Plant Expression Constructs
08/16/2012US20120209223 Transdermal therapeutic system for administration of fentanyl or an analog thereof
08/16/2012US20120209050 Novel pyridopyrazine derivatives, process of manufacturing and uses thereof
08/16/2012US20120209027 Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid
08/16/2012US20120209012 Compounds, compositions and methods
08/16/2012US20120208993 Synthetic heparin trisaccharides
08/16/2012US20120208893 Nutritional compositions for modulating inflammation including exogenous vitamin k2
08/16/2012US20120208892 Emesis treatment
08/16/2012US20120208891 Methods for concomitant administration of colchicine and a second active agent
08/16/2012US20120208889 Class- and isoform-specific hdac inhibitors and uses thereof
08/16/2012US20120208887 Stable, liquid, ready-to-use ketoprofen formulations
08/16/2012US20120208886 Moisture Resistant Container Systems for Rapidly Bioavailable Dosage Forms
08/16/2012US20120208885 L-ornithine phenyl acetate and methods of making thereof
08/16/2012US20120208884 Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
08/16/2012US20120208883 Treatment of oncological diseases
08/16/2012US20120208882 Organic Compounds
08/16/2012US20120208881 Methods for concomitant administration of colchicine and a second active agent
08/16/2012US20120208880 (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
08/16/2012US20120208879 Methods and pharmaceutical compositions useful for treating psoriasis
08/16/2012US20120208878 Medical composition
08/16/2012US20120208877 Skin treatment in antiseptic thin film form with silver
08/16/2012US20120208876 Amino acid derivatives for the treatment of neuropathic pain
08/16/2012US20120208875 Method for inhibiting blood vessel stenosis
08/16/2012US20120208873 Tea polyphenols products for ceasing smoking and treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
08/16/2012US20120208872 Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
08/16/2012US20120208871 Use of toll-like receptor and agonist for treating cancer
08/16/2012US20120208868 Purification process of nascent dna
08/16/2012US20120208867 Hmgb1 binding nucleic acid molecule and applications thereof
08/16/2012US20120208866 Intact minicells as vectors for dna transfer and gene therapy invitro and invivo
08/16/2012US20120208865 Exon skipping therapy for dysferlinopathies
08/16/2012US20120208864 Compounds and methods for modulating expression of gcgr
08/16/2012US20120208863 Modulation of glut4 gene promoter activity by ahnak
08/16/2012US20120208862 Rip140 regulation of glucose transport
08/16/2012US20120208861 Ifn type-i production inhibitor and method for screening for same
08/16/2012US20120208860 Compositions and methods for inhibiting expression of factor vii gene
08/16/2012US20120208859 Novel mek inhibitors useful in the treatment of diseases
08/16/2012US20120208858 Pharmaceutical Cream Compositions of Oxymetazoline and Methods of Use
08/16/2012US20120208857 Pharmaceutical Compositions
08/16/2012US20120208856 Heterocyclic Benzoxazole Compositions as Inhibitors of Hepatitis C Virus
08/16/2012US20120208855 Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
08/16/2012US20120208854 Therapeutic combination
08/16/2012US20120208852 Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
08/16/2012US20120208851 Formulations
08/16/2012US20120208850 Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
08/16/2012US20120208849 Methods for controlling pain in canines using a transdermal solution of fentanyl
08/16/2012US20120208848 Gacyclidine formulations
08/16/2012US20120208847 Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process
08/16/2012US20120208846 Therapeutic Methods For Type I Diabetes
08/16/2012US20120208844 Substituted piperidines that increase p53 activity and the uses thereof
08/16/2012US20120208843 Method of Using GPR35 to Identify Metabolic-Stabilizing Compounds
08/16/2012US20120208842 Novel 1-(1-OXO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)Urea Derivatives As N-FORMYL Peptide Receptor Like-1 (FPRL-1) Receptor Modulators
08/16/2012US20120208841 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
08/16/2012US20120208840 Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors
08/16/2012US20120208839 New compounds
08/16/2012US20120208838 Diuretics
08/16/2012US20120208837 Substituted azaindoles
08/16/2012US20120208836 Compositions and methods for the treatment of obesity and related disorders
08/16/2012US20120208835 Method and dosage regimens for eliminating a chemical substance in blood
08/16/2012US20120208834 Process for preparing spray dried formulations of 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile
08/16/2012US20120208833 4-(Substituted Anilino)-Quinazoline Derivatives Useful as Tyrosine Kinase Inhibitors
08/16/2012US20120208832 Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
08/16/2012US20120208831 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
08/16/2012US20120208830 Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
08/16/2012US20120208829 2-phenoxy pyrimidinone analogues
08/16/2012US20120208828 Azole Derivatives as WTN Pathway Inhibitors
08/16/2012US20120208827 Benzimidazoles as fatty acid synthase inhibitors
08/16/2012US20120208826 Heterocyclic amide compounds as protein kinase inhibitors
08/16/2012US20120208825 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
08/16/2012US20120208824 ROS Kinase in Lung Cancer
08/16/2012US20120208823 New Compounds
08/16/2012US20120208822 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
08/16/2012US20120208821 Alpha adrenergic receptor modulators
08/16/2012US20120208820 Diazabicyclic central nervous system active agents
08/16/2012US20120208819 Heterocyclic compounds useful as pdk1 inhibitors
1 ... 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 ... 7860